Oncolytic virotherapy approved in Uzbekistan

In the April year 2018 Chief Directorate of medicines and medical equipment quality control, a subdivision of Ministry of Health in the Uzbekistan Republic has been approved Latvian oncolytic virotherapy medicine RIGVIR® for the treatment of cancer. In Uzbekistan, 23,000 new cases of cancer are discovered annually and Uzbek medical specialists highly appreciate the fact that now there is a safe, gentle and effective treatment available for cancer patients in Uzbekistan.

Contacts for Media Inquiries

Rigvir Group
Address: 9-7 Teatra street, LV–1050, Riga, Latvia
Phone: +371 67 229 599
E-mail: pr@rigvir.com